Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Summit DMD Data Intrigue But Longer-Term Results Awaited

Executive Summary

Early data for ezutromid in Duchenne muscular dystrophy product give some proof of concept as a broad treatment for the fatal genetic disease – more data are awaited as Summit steps up its pivotal trial plans.


Related Content

In DMD, Summit Falls Well Short Of Peak It Hoped For
Santhera Braced For Another CHMP No In Duchenne
Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts